Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cell Therapy in Relapsed/Refractory Myeloma With Extramedullary Disease
NCT05666700Phase 1Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2023
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ciltacabtagene autoleucel in extramedullary myeloma (EMM), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Utility of 64Cu SPION labelling for in vivo real time monitoring of trafficking of anti-BCMA CAR-T cells at 1 month. Started Dec 2023; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
extramedullary myeloma (EMM)
Beyond the preview
Go deeper on NCT05666700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666700.